Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.L. Veenstra
Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
Pcn76 - Budget Impact Analysis of Afatinib for the First-Line Treatment of Advanced or Metastatic Non–small-Cell Lung Cancer in China
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Impact of Initial Gefitinib or Erlotinib Versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Clinical Cancer Research
Cancer Research
Oncology
Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Pcn44 - First-Line Treatment Efficacy in Egfr-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared With Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
PLoS ONE
Multidisciplinary
Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Immunotherapy
Oncology
Allergy
Immunology
Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial
The Lancet
Medicine
